Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Common Equity: 2022-2024

Historic Common Equity for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $71.5 million.

  • Taysha Gene Therapies' Common Equity rose 146.62% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 146.62%. This contributed to the annual value of $71.5 million for FY2024, which is 4.55% down from last year.
  • Taysha Gene Therapies' Common Equity amounted to $71.5 million in FY2024, which was down 4.55% from $74.9 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Common Equity high stood at $74.9 million for FY2023, and its period low was $949,000 during FY2022.
  • For the 3-year period, Taysha Gene Therapies' Common Equity averaged around $49.1 million, with its median value being $71.5 million (2024).
  • In the last 5 years, Taysha Gene Therapies' Common Equity skyrocketed by 7,796.42% in 2023 and then declined by 4.55% in 2024.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Common Equity stood at $949,000 in 2022, then spiked by 7,796.42% to $74.9 million in 2023, then declined by 4.55% to $71.5 million in 2024.